Polar Asset Management Partners Inc. Reduces Stock Holdings in argenx SE (NASDAQ:ARGX)

Polar Asset Management Partners Inc. lessened its position in argenx SE (NASDAQ:ARGX - Free Report) by 39.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,547 shares of the company's stock after selling 3,600 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in argenx were worth $3,411,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Point72 Europe London LLP bought a new stake in shares of argenx in the 4th quarter worth about $5,839,000. Stephens Inc. AR bought a new stake in shares of argenx in the 4th quarter worth about $310,000. Jones Financial Companies Lllp lifted its holdings in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after acquiring an additional 61 shares during the last quarter. Atomi Financial Group Inc. bought a new stake in shares of argenx in the 4th quarter worth about $339,000. Finally, Ameriprise Financial Inc. lifted its holdings in shares of argenx by 10.0% in the 4th quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock worth $4,313,000 after acquiring an additional 639 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Baird R W upgraded shares of argenx from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Guggenheim reduced their price target on shares of argenx from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, William Blair restated an "outperform" rating on shares of argenx in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, twenty have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, argenx has an average rating of "Buy" and a consensus price target of $698.11.

argenx Price Performance

NASDAQ:ARGX traded down $3.53 during trading hours on Wednesday, hitting $576.24. 230,594 shares of the company were exchanged, compared to its average volume of 325,666. The stock has a market capitalization of $35.19 billion, a price-to-earnings ratio of -654.82 and a beta of 0.57. argenx SE has a 52-week low of $359.37 and a 52-week high of $678.21. The company's 50 day moving average price is $587.69 and its 200-day moving average price is $612.60.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.26. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities analysts predict that argenx SE will post 3.13 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.